1-5 of 5
Bin Peng
Close
Sort by
Journal Articles

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

Byung-Sik Cho, Zhihong Zeng, Hong Mu, Zhiqiang Wang, Sergej Konoplev, Teresa McQueen, Marina Protopopova, Jorge Cortes, Joseph R. Marszalek, Sheng-Bin Peng, Wencai Ma, R. Eric Davis, Donald E. Thornton, Michael Andreeff, Marina Konopleva
Journal: Blood
Blood (2015) 126 (2): 222–232.
https://doi.org/10.1182/blood-2015-02-628677
Published: 2015
Includes: Supplemental data
Journal Articles

Pronounced Anti-Leukemia Activity in Vivo of the Novel Peptidic CXCR4 Antagonist LY2510924 As a Single Agent and in Combination with Chemotherapy

Byung-Sik Cho, Zhihong Zeng, MD, Hong Mu, MD PhD, Zhiqiang Wang, Teresa McQueen, BS, Marina Protopopova, Jorge E. Cortes, MD, Joe Marszalek, Sheng-Bin Peng, Richard Eric Davis, Donald Thornton, MD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3745.
https://doi.org/10.1182/blood.V124.21.3745.3745
Published: 2014
Journal Articles

A Phase I Study To Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Oral Platelet Growth Factor (SB-559448) in Healthy Subjects.

Sheng-Fang Su, PhD, Bin Peng, MD, PhD, Daphne Williams, Jung Wook Park, Malcolm L. Handel, BSc, MB BS, PhD, Julian Jenkins, MS, Peter Ho, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 1072.
https://doi.org/10.1182/blood.V108.11.1072.1072
Published: 2006
Journal Articles

A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.

Francis J. Giles, MD, Thomas Fischer, MD, Jorge Cortes, MD, James Beck, MD, Farhad Ravandi-Kashani, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Bin Peng, PhD, Patricia E. Rae, BSc, Glen Laird, Samil Sharma, MD, Margaret Dugan, MD, Maher Albitar, MD, Kapil M. Bhalla, MD
Journal: Blood
Blood (2004) 104 (11): 1802.
https://doi.org/10.1182/blood.V104.11.1802.1802
Published: 2004
Journal Articles

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

Clinical Trials & Observations
Martin A. Champagne, Renaud Capdeville, Mark Krailo, Wenchun Qu, Bin Peng, Marianne Rosamilia, Martine Therrien, Ulrike Zoellner, Susan M. Blaney, Mark Bernstein
Journal: Blood
Blood (2004) 104 (9): 2655–2660.
https://doi.org/10.1182/blood-2003-09-3032
Published: 2004